The Efficacy and Safety of Thymosin Alpha 1 for Sepsis: a Multicenter , Double-Blinded, Randomized and Controlled Clinical Trial

Next Previous
Trial Profile

The Efficacy and Safety of Thymosin Alpha 1 for Sepsis: a Multicenter , Double-Blinded, Randomized and Controlled Clinical Trial

Recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Thymalfasin (Primary)
  • Indications Sepsis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TESTS

    • Most Recent Events

    • 26 Sep 2016 According to a SciClone Pharmaceuticals media release, the company anticipates completing enrollment in the trial in 2018, with data potentially available in 2019. A positive outcome in this Phase III trial could lead to inclusion of ZADAXIN in the China Sepsis Treatment Guidelines.
    • 26 Sep 2016 According to a SciClone Pharmaceuticals media release, first patient has been treated in the study.
    • 26 Sep 2016 Status changed from not yet recruiting to recruiting, according to a SciClone Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top